U.S. Ambulatory Surgery Centre Market is estimated to be valued at USD 72.58 Bn in 2025 and is expected to reach USD 103.5 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 5.2% from 2025 to 2032.
The U.S. Ambulatory Surgery Centre (ASC) Market is experiencing strong growth, driven by rising demand for outpatient procedures that offer cost savings, efficiency, and reduced hospital stays. Favourable reimbursement policies, physician ownership models, and increasing investment in ASC infrastructure are accelerating adoption, positioning ASCs as a vital component of the evolving U.S. healthcare landscape.
|
Current Event |
Description and its impact |
|
Digital Transformation and Equipment Modernization |
|
|
Network Expansion and Strategic Alliances |
|
|
Policy Shifts and Financial Incentives |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The U.S. Ambulatory Surgery Centre (ASC) market is witnessing an active development pipeline, driven by healthcare providers’ strategic shift toward cost-efficient outpatient care models. Multiple new multispecialty and single-specialty ASCs are under development across high-density urban areas and underserved rural regions to meet rising patient demand and reduce hospital burden. Strategic partnerships between private equity firms, hospital networks, and physician groups are accelerating project approvals and construction timelines.
Technological advancements in robotic surgery, imaging systems, and anaesthesia are also influencing the pipeline, with many upcoming ASCs incorporating state-of-the-art infrastructure to support complex procedures in outpatient settings.
Moreover, pipeline centres are increasingly being designed with digital integration, telehealth compatibility, and value-based care frameworks to align with U.S. Ambulatory Surgery Centre Market payer reimbursement policies. As reimbursement structures evolve to incentivize outpatient services, developers are tailoring new centres to meet these criteria, ensuring financial sustainability and expanded access. The ASC pipeline is expected to grow steadily through 2030, particularly in orthopaedics, cardiovascular, and gastroenterology specialties.
The patent landscape of the U.S. Ambulatory Surgery Centre (ASC) market reflects a dynamic ecosystem of innovation focused on improving efficiency, safety, and patient outcomes in outpatient surgical environments. Key patent filings over the past five years involve advanced surgical tools, portable diagnostic devices, real-time monitoring systems, and integrated data platforms specifically tailored for ASC use.
Innovations in minimally invasive procedures, robotic-assisted surgery, and sterilization equipment are frequently patented by leading medical device firms aiming to expand their presence in ASCs.
Additionally, patents related to workflow automation, electronic health record (EHR) integration, and remote patient monitoring are gaining traction, supporting the digital transformation of outpatient care.
Start-ups and mid-sized medtech companies are actively contributing to the IP landscape, often collaborating with physician-led ASC networks to co-develop proprietary technologies. As ASCs continue to expand their scope of procedures, IP development remains critical to securing competitive advantages and driving future growth.
The reimbursement landscape for U.S. Ambulatory Surgery Centres (ASCs) is evolving in response to healthcare cost containment strategies and the shift toward value-based care. The Centres for Medicare & Medicaid Services (CMS) continues to expand the list of reimbursable procedures in ASCs, including cardiovascular, orthopaedic, and gastrointestinal surgeries. This expansion has significantly enhanced the financial viability of ASCs by incentivizing outpatient care over hospital-based alternatives.
Private payers are also aligning with CMS by offering bundled payments and shared savings models to encourage efficient, high-quality surgical care. Reimbursement rates for ASCs are generally lower than those for hospital outpatient departments (HOPDs), offering cost advantages for payers and patients alike.
However, challenges persist, including complex billing codes, documentation requirements, and varying reimbursement structures across states and insurers. Despite these hurdles, continued regulatory support and payer collaboration are expected to drive further adoption and profitability of ASCs in the coming years.
Prescribers across the United States are increasingly favouring Ambulatory Surgery Centres (ASCs) due to their efficiency, reduced patient wait times, and streamlined workflows. Physicians value ASCs for offering greater control over scheduling, access to specialized staff, and state-of-the-art surgical equipment tailored to outpatient procedures. This autonomy allows prescribers to deliver care in a patient-centric environment while maintaining high clinical standards.
Additionally, ASCs enable quicker turnover of cases and lower overhead costs compared to traditional hospital settings, which appeals to both individual practitioners and group practices. For specialists in fields such as orthopaedics, ophthalmology, gastroenterology, and pain management, ASCs offer the flexibility to handle high volumes with minimal administrative burden.
The preference is further reinforced by favourable patient outcomes, reduced risk of hospital-acquired infections, and consistent reimbursement frameworks. As minimally invasive techniques become more widespread, physician inclination toward ASCs is expected to grow, strengthening the outpatient surgical care ecosystem.
Increasing prevalence of chronic diseases are expected to drive the market growth thus Market players are adopting strategies such as new product launches, and this is expected to drive the market growth. According to the WHO, increasing incidence rate of neurogenerative diseases such as Parkinson's disease, Alzheimer's disease, and dementiais expected to drive the market growth.
For instance, an article published by Springer Nature on September 12, 2020 Chronic pain is very common and has traditionally been managed with daily opioid regimens. It is estimated that up to 30% of patients presenting for elective surgery use long-term opioids.
Strategic activities including product launches, mergers & acquisitions, collaborations, and others is expected to drive the market growth. For instance, in January 2021 HST Pathways, a cloud-based ambulatory surgery centre software company, launched HST One, a premium membership programme for ambulatory surgical centres (ASCs).
The end users of this membership programme will have the option to choose popular items that are packaged together as part of their membership, with the option to add on additional services as necessary. The introduction of personalized care in ambulatory surgery centres will attract more patients and lead to significant market growth.
Multispecialty ambulatory surgery centres are projected to dominate the U.S. ASC market, capturing around 65.0% of the total share by 2025. These facilities provide a wide range of surgical services spanning orthopaedics, gastroenterology, ophthalmology, urology, and pain management within a single centre, enhancing operational efficiency and patient convenience.
The ability to accommodate varied procedure types under one roof makes multispecialty centres ideal for maximizing equipment utilization and streamlining scheduling logistics. Their modular infrastructure, scalable design, and cross-specialty appeal have attracted significant investor interest and led to accelerated expansion across both urban and suburban regions.
Additionally, supportive regulatory policies, strategic payer-provider collaborations, and higher margins compared to single-specialty centres are expected to keep multispecialty ASCs at the forefront of outpatient surgical care in the U.S.
Cardiovascular procedures are expected to constitute approximately 18.0% of all surgeries performed in U.S. ambulatory surgery centres (ASCs) by 2025. This growth is attributed to the increasing shift of complex interventions—such as cardiac ablation, angioplasty, and pacemaker implants—into outpatient settings. Technological advancements in minimally invasive techniques, combined with shorter recovery times, have made ASCs a viable and cost-effective alternative to hospital-based care.
The integration of digital transformation in U.S. Ambulatory Surgery Centres, including remote monitoring, AI-assisted diagnostics, and electronic health record (EHR) interoperability, is playing a pivotal role in enhancing cardiovascular care delivery. These digital tools not only improve procedural accuracy and post-operative follow-up but also support patient engagement and data-driven decision-making.
Enhanced reimbursement frameworks from public and private insurers, along with growing patient trust in outpatient cardiovascular care, further strengthen this segment’s upward trajectory. The emphasis on value-based care and early discharge protocols is also expected to expand the range of cardiovascular services offered in ASCs moving forward.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 72.58 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.2% | 2032 Value Projection: | USD 103.5 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AmSurg Corp., Getinge Group, Tenet Healthcare, Regent surgery Health L.L.C, Covenant surgery Partners Inc, and Surgery Partners |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients